Not approved & not recommended for the treatment of dementia-related psychosis &/or behavioural disturbances. Not recommended in the treatment of dopamine agonist-associated psychosis in patients w/ Parkinson's disease. Very rare reports of hyperglycaemia &/or development or exacerbation of diabetes. Reports of cerebrovascular adverse events. Risk of transient, asymptomatic elevations of ALT &/or AST, especially in early treatment; tardive dyskinesia especially w/ long-term exposure; VTE; DRESS. Caution in patients w/ prostatic hypertrophy, or paralytic ileus & related conditions; low leukocyte &/or neutrophil counts for any reason, history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, RT or chemotherapy, hypereosinophilic conditions or myeloproliferative disease; patients w/ history of seizures or are subject to factors which may lower the seizure threshold; renal &/or hepatic impairment; elderly ≥65 yr. Discontinue treatment in case of signs & symptoms indicative of NMS or unexplained high fever w/o additional clinical manifestations of NMS. Periodically measure BP in patients >65 yr. Acute symptoms eg, sweating, insomnia, tremor, anxiety, nausea, or vomiting w/ abrupt treatment discontinuation. Limited data on co-medication w/ lithium & valproate. No clinical data available on olanzapine & carbamazepine co-therapy. Caution w/ concomitant medicines known to cause neutropenia; other centrally acting medicines & alcohol; direct & indirect dopamine agonists; medicinal products known to increase QTc interval. Contains aspartame, which may be harmful to patients w/ phenylketonuria. May affect ability to drive & use machines. Neonates exposed to antipsychotic drugs during the 3rd trimester of pregnancy are at risk for extrapyramidal &/or w/drawal symptoms following delivery. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Do not breast-feed while on treatment. No experience in childn.
Sign Out
